[go: up one dir, main page]

MXPA05013865A - Formulaciones liofilizadas de cci-779. - Google Patents

Formulaciones liofilizadas de cci-779.

Info

Publication number
MXPA05013865A
MXPA05013865A MXPA05013865A MXPA05013865A MXPA05013865A MX PA05013865 A MXPA05013865 A MX PA05013865A MX PA05013865 A MXPA05013865 A MX PA05013865A MX PA05013865 A MXPA05013865 A MX PA05013865A MX PA05013865 A MXPA05013865 A MX PA05013865A
Authority
MX
Mexico
Prior art keywords
cci
formulations
lyophilized formulations
lyophilized
methods
Prior art date
Application number
MXPA05013865A
Other languages
English (en)
Inventor
Joseph T Rubino
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34115376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA05013865(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MXPA05013865A publication Critical patent/MXPA05013865A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se describen formulaciones de CCI-779 liofilizadas y soluciones utiles para preparar formulaciones de CCI-779 secadas por congelamiento compuestas de CCI-779, y un solvente seleccionado de dimetilsulfoxido, acetonitrilo, etanol, isopropanol o alcohol t-butilico. Tambien se proporcionan los metodos para preparar las formulaciones de CCI-779 liofilizadas, metodos para reconstituir las mismas y usos para las mismas.
MXPA05013865A 2003-07-25 2004-07-15 Formulaciones liofilizadas de cci-779. MXPA05013865A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49029303P 2003-07-25 2003-07-25
PCT/US2004/023773 WO2005011688A1 (en) 2003-07-25 2004-07-15 Cci-779 lyophilized formulations

Publications (1)

Publication Number Publication Date
MXPA05013865A true MXPA05013865A (es) 2006-02-28

Family

ID=34115376

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05013865A MXPA05013865A (es) 2003-07-25 2004-07-15 Formulaciones liofilizadas de cci-779.

Country Status (20)

Country Link
US (1) US20050020615A1 (es)
EP (1) EP1648454A1 (es)
JP (1) JP2007500191A (es)
KR (1) KR20060052880A (es)
CN (1) CN1829514A (es)
AR (1) AR045094A1 (es)
AU (1) AU2004261163A1 (es)
BR (1) BRPI0412916A (es)
CA (1) CA2532251A1 (es)
CO (1) CO5680425A2 (es)
CR (1) CR8153A (es)
EC (1) ECSP066394A (es)
IL (1) IL172573A0 (es)
MX (1) MXPA05013865A (es)
NO (1) NO20056178L (es)
RU (1) RU2345772C2 (es)
SG (1) SG144165A1 (es)
TW (1) TW200505501A (es)
WO (1) WO2005011688A1 (es)
ZA (1) ZA200600684B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI307277B (en) 2002-07-30 2009-03-11 Wyeth Corp Parenteral formulations
EP1701698B1 (en) * 2004-01-08 2008-01-16 Wyeth a Corporation of the State of Delaware Directly compressible pharmaceutical composition for the oral admimistration of cci-779
EP1781672B1 (en) 2004-08-27 2010-10-06 Cordis Corporation Solvent free amorphous rapamycin
US7582312B2 (en) * 2004-11-15 2009-09-01 Discovery Laboratories, Inc. Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof
US7464012B2 (en) * 2004-12-10 2008-12-09 L'air Liquide, Societe Anonyme A Directoire Et Conseil De Surveillance Pour L'etude Et L'exploitation Des Procedes Georges Claude Simplified process simulator
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
CN102164579B (zh) 2008-09-25 2014-10-15 赛福伦公司 苯达莫司汀的液体配制品
EP2387400A1 (en) * 2009-01-15 2011-11-23 Cephalon, Inc. Novel forms of bendamustine free base
WO2011151704A2 (en) * 2010-06-02 2011-12-08 Fresenius Kabi Oncology Ltd. Stable pharmaceutical compositions of rapamycin esters
WO2013117969A1 (en) 2012-02-06 2013-08-15 Fresenius Kabi Oncology Ltd. Process for preparing stable pharmaceutical compositions of compounds susceptible to hydrolysis
CN102940630A (zh) * 2012-11-16 2013-02-27 浙江海正药业股份有限公司 含有西罗莫司酯化物的药物组合物及其制备方法
WO2014118696A2 (en) * 2013-01-29 2014-08-07 Gland Pharma Limited Pharmacuetical compositions of rapamycin esters and its derivatives
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
CN104510708B (zh) * 2013-09-29 2018-04-24 正大天晴药业集团股份有限公司 一种米铂冻干制剂及其制备方法
US10342769B2 (en) 2014-11-14 2019-07-09 Navinta Iii Inc Carmustine pharmaceutical composition
WO2017129772A1 (en) 2016-01-29 2017-08-03 Xellia Phamaceuticals Aps Stable pharmaceutical compositions of temsirolimus
CN105687132B (zh) * 2016-03-17 2020-06-12 鲁南贝特制药有限公司 一种坦西莫司注射用浓溶液及其制备方法
CN107773539A (zh) * 2016-08-27 2018-03-09 鲁南制药集团股份有限公司 一种注射用坦西莫司及其制备方法
CN111165656A (zh) * 2020-01-09 2020-05-19 南京大学（溧水）生态环境研究院 一种黑水虻冻干粉高效制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1204775B (it) * 1986-01-31 1989-03-10 Rosella Silvestrini Kit per la determinazione dell'attivita' proliferativa nei tumori umani
US5352783A (en) * 1993-06-09 1994-10-04 Merck & Co., Inc. Microbial transformation product having immunosuppressive activity
US5362735A (en) * 1994-02-23 1994-11-08 Smithkline Beecham Corporation Rapamycin derivatives
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
ES2187660T3 (es) * 1995-06-09 2003-06-16 Novartis Ag Derivados de rapamicina.
GB9514594D0 (en) * 1995-07-17 1995-09-13 Johnson & Johnson Clin Diag Chemiluminescent analytical method
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
DE19936281C2 (de) * 1999-08-02 2002-04-04 Bayer Ag Verfahren zur Gefriertrocknung
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
GB0008785D0 (en) * 2000-04-10 2000-05-31 Novartis Ag Organic compounds
PT1318837E (pt) * 2000-08-11 2004-12-31 Wyeth Corp Metodo de tratamenton de carcinoma positivo a receptor de estrogenio
US6399625B1 (en) * 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI307277B (en) * 2002-07-30 2009-03-11 Wyeth Corp Parenteral formulations
MXPA05002828A (es) * 2002-09-17 2005-05-27 Wyeth Corp Formulaciones orales.
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція

Also Published As

Publication number Publication date
TW200505501A (en) 2005-02-16
US20050020615A1 (en) 2005-01-27
KR20060052880A (ko) 2006-05-19
CA2532251A1 (en) 2005-02-10
NO20056178L (no) 2006-02-17
ECSP066394A (es) 2006-08-30
AU2004261163A1 (en) 2005-02-10
WO2005011688A1 (en) 2005-02-10
IL172573A0 (en) 2006-04-10
CR8153A (es) 2006-05-26
AR045094A1 (es) 2005-10-12
EP1648454A1 (en) 2006-04-26
RU2345772C2 (ru) 2009-02-10
BRPI0412916A (pt) 2006-09-26
JP2007500191A (ja) 2007-01-11
RU2006105645A (ru) 2006-06-27
SG144165A1 (en) 2008-07-29
CO5680425A2 (es) 2006-09-29
ZA200600684B (en) 2008-07-30
CN1829514A (zh) 2006-09-06

Similar Documents

Publication Publication Date Title
SG144165A1 (en) Cci-779 lyophilized formulations
WO2003057163A3 (en) Methods for preparing immunoconjugates
MXPA02009275A (es) Metodo para preparar dispersiones de alta presion/alto esfuerzo cortante que contienen ingredientes fisiologicamente activos.
WO2007059008A3 (en) N-substituted indenoisoquinolines and syntheses thereof
WO2005047494A3 (en) Haematopoietic stem cells suitable for transplantation, their preparation and pharmaceutical compositions comprising them
WO2002002596A3 (en) Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them
WO2005033112A3 (en) Substituted indole derivatives
WO2003084926A3 (en) Polymeric acyl derivatives of indoles
AU2002361366A1 (en) Compensated, digital class d amplifier
WO2005056763A3 (en) Process and formulation to improve viability of stored cells and tissue
WO2005060981A3 (en) Pharmaceutical compositions
UA83672C2 (en) Cci-779 lyophilized formulations
AU2002217863A1 (en) Homing peptide multimers, their preparation and uses
WO2004060051A3 (en) Hybrid cotton plants and seeds, and methods and systems of generating same
AU2002320079A1 (en) Vaccines, immunotherapeutics and methods of using the same
AU2003254781A1 (en) Aminosalicylamide derivative, process for producing the same and agri-horticultural pesticide
WO2002057281A3 (en) Aminoglycosides as antibiotics
MXPA02011191A (es) Vacunas, inmunoterapeuticos, y metodos de uso de los mismos.
WO2004078714A3 (en) Processes for preparing imidazoquinoxalinones, heterocyclic-substituted imidazopyrazinones, imidazouinoxalines and heterocyclic-substituted imidazopyrazines
AU2003245057A1 (en) 2-thioxothiazole derivative, method for preparing the same, and pharmaceutical composition containing the same
AU2003300701A1 (en) Beta-carboline derived guanidine alkaloid, tiruchenduramine
TW200724152A (en) Oligopeptide, derivative thereof, and pharmaceutical composition comprising the same
AU2003232684A1 (en) Pyrazole-3-one derivative, method for preparing the same, and pharmaceutical composition containing the same
AU4692501A (en) Laminaribiose phosphorylase, process for producing the same and process for producing laminarioligosaccharide by using the enzyme
WO2005023196A3 (en) Compounds and methods